Man Group plc Boosts Stake in Encompass Health Co. (NYSE:EHC)

Man Group plc raised its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 53.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,407 shares of the company's stock after buying an additional 19,217 shares during the quarter. Man Group plc owned approximately 0.05% of Encompass Health worth $5,117,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. acquired a new stake in Encompass Health during the fourth quarter worth about $152,953,000. Norges Bank purchased a new stake in shares of Encompass Health in the 4th quarter valued at approximately $100,637,000. Raymond James Financial Inc. acquired a new stake in shares of Encompass Health during the 4th quarter worth approximately $77,944,000. Jennison Associates LLC purchased a new stake in shares of Encompass Health during the 4th quarter valued at approximately $52,094,000. Finally, Farallon Capital Management LLC lifted its holdings in Encompass Health by 15,266.7% in the fourth quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock valued at $42,573,000 after acquiring an additional 458,000 shares during the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. KeyCorp lifted their target price on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Truist Financial reissued a "buy" rating and set a $135.00 price objective (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Wall Street Zen raised shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays increased their target price on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, UBS Group boosted their price target on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $120.86.

Insider Buying and Selling

In related news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the transaction, the chief executive officer now owns 527,070 shares of the company's stock, valued at $64,054,817.10. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president now directly owns 79,710 shares of the company's stock, valued at $9,149,910.90. This trade represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,663 shares of company stock worth $16,034,082. Company insiders own 2.00% of the company's stock.

Encompass Health Stock Up 0.1%

Shares of NYSE EHC traded up $0.13 during midday trading on Monday, hitting $118.74. The company's stock had a trading volume of 388,011 shares, compared to its average volume of 699,207. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The firm has a market capitalization of $11.97 billion, a price-to-earnings ratio of 26.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The business's fifty day simple moving average is $107.85 and its two-hundred day simple moving average is $101.40. Encompass Health Co. has a 1 year low of $82.74 and a 1 year high of $121.96.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company's revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 earnings per share. On average, equities analysts predict that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's payout ratio is presently 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.